The text provides financial information from Bristol-Myers Squibb Company, including consolidated statements of earnings, comprehensive income, balance sheets, and cash flows for the period ending September 30, 2023. Key figures such as net product sales, total revenues, expenses, earnings before income taxes, net earnings, and comprehensive income are detailed. Information on assets, liabilities, and equity is also included, along with revenue disaggregation, GTN adjustments, revenue by product and region, and recently adopted accounting standards. The Company operates in a single segment focusing on medicines for serious diseases, with the CEO managing operational resources at a global corporate level. The financial statements are prepared in compliance with SEC and U.S. GAAP standards, with estimates, judgments, and reclassifications made for clarity. Additionally, the text outlines the use of derivative contracts like foreign currency forward contracts and put options to hedge against currency exchange rate risks associated with international transactions, with fair values recorded in the balance sheets. Cross-currency swap contracts are used to hedge long-term debt exposure, with effectiveness assessments periodically conducted. The text also discusses the discontinuation of cash flow hedges under certain circumstances, the impact of these hedges on financial statements, and provides details on the company's financing arrangements and various assets.
The provided text refers to the "Management's Discussion and Analysis of Financial Condition and Results of Operations" of a pharmaceutical company, presenting an overview of its executive summary, financial performance, strategic initiatives, detailed financial results, product developments, and critical accounting policies. It also reflects on economic factors, governmental actions affecting the industry, and details on the company's financial position, liquidity, capital resources, and future goals. Additionally, it covers information related to financial activities, cash flow analysis, product and pipeline developments, special notes on forward-looking statements, and a disclaimer on the information presented. The company emphasizes the importance of understanding the uncertainties associated with forward-looking statements and acknowledges the inherent risks that could impact its actual financial performance.
Refer to section "Item 7A" in the 2022 Form 10-K for detailed information on the quantitative and qualitative disclosures regarding market risk.
Management evaluated the effectiveness of the design and operation of disclosure controls and procedures, as defined by Exchange Act Rules, with the CEO and CFO's supervision and participation. They concluded that as of September 30, 2023, these controls and procedures were effective. There were no significant changes in the company's internal control over financial reporting during the quarter that ended on September 30, 2023.
The text mentions that information about legal proceedings can be found in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies," within the interim consolidated financial statements, and is incorporated by reference.
The text states that there have been no significant alterations in the risk factors disclosed in the Company's 2022 Form 10-K.
The text provides a summary of the unregistered sales of equity securities and the use of proceeds for a company during the three months ending September 30, 2023. It includes information about the total number of shares purchased, the average price paid per share, publicly announced programs, and the approximate dollar value of shares that may still be purchased under the programs. The company's repurchase programs and authorizations are detailed, noting that the Board of Directors had authorized the repurchase of up to $3.0 billion of common stock and subsequently approved additional authorizations. In August 2023, the company executed accelerated share repurchase agreements for $4.0 billion of common stock.
I am ready to summarize the text for you. Please provide me with the text you would like me to summarize.
I'm sorry, but I cannot process the text you have provided as there are no parts for me to summarize. Please provide me with the full text you would like me to summarize.
No directors or officers of the company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" during the period covered by the Quarterly Report on Form 10-Q. The Company entered into ASR agreements in the third quarter of 2023, intended to be Rule 10b5-1 trading arrangements. For more details on these transactions, refer to "Item 2. Unregistered Sales of Equity Securities and Use of Proceeds."
The text provides a list of exhibits included in a filing, along with a summary of abbreviated terms commonly used in the document, such as definitions for various pharmaceutical terms like ANDA and NDA. There is also a section related to brand name trademarks and a signature section indicating that the report was signed by the Chairman of the Board and CEO, Giovanni Caforio, as well as the Chief Financial Officer, David V. Elkins, on behalf of Bristol-Myers Squibb Company.
